Role of miR153 and miR455-5p Expression in Oral Squamous Cell Carcinoma Isolated from Plasma

Baber, S; Bayat, Mohammad; Mohamadnia, Abdolreza; Shamshiri, Ahmadreza; Shakib, Pouyan Amini; Bahrami, Naghmeh

doi:10.31557/apjcp.2021.22.1.157

Cited by 7 publications

(3 citation statements)

References 25 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there is no direct evidence that hsa-miR-455-5p is associated with plasma exosomes of LSCC, however, studies have con rmed that it is highly expressed in laryngeal cancer, the expression level is more signi cant than that of adjacent noncancerous counterparts and benign laryngeal tissues [39], and is associated with prognosis [40]. Furthermore, hsa-miR-455-5p isolated from plasma has been proved to be an early diagnostic indicator of OSCC [41]. It may regulate the OSCC cell proliferation and promote the OSCC tumorigenesis through affecting PTPRS related pathway and transforming growth factor-β (TGF-β) pathway, these pathways were also common in HNSCC [42].…”

Section: Discussionmentioning

confidence: 99%

Sequencing and validation of exosomal miRNAs panel as novel plasma biomarkers for early diagnosis and prognosis prediction in laryngeal cancer

Zhang

Chen

Huang

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose Plasma exosomal miRNAs are important biomarkers for body fluid biopsy. The purpose of this study was to screen and construct plasma exosomal miRNAs panel as biomarkers for diagnosis and prognosis in laryngeal squamous cell carcinoma (LSCC). Methods Plasma exosomal miRNAs from 6 LSCC patients with three typical anatomical sites and 3 normal controls (NC) were analyzed by next-generation sequencing. The obtained aberrant expression profile of exosomal miRNAs were compared with the online databases of LSCC to construct and verify the diagnostic and prognostic panel by machine learning. Also, quantitative real-time polymerase chain reaction (qRT-PCR) was applied to validate the diagnostic efficacy of the screened miRNAs in an independent clinical cohort. Results A plasma exosomal miRNAs panel (consisting of hsa-miR-139-3p, hsa-miR-486-5p, hsa-miR-944, hsa-miR-320b and hsa-miR-455-5p) was successfully constructed for early diagnosis and prognosis of LSCC, and showed good predictive potential with an AUC of 0.782, 1.000, 0.716, and 0.875 by artificial neural network (ANN) panel in the independent datasets. This panel was further validation in an independent cohort consisting of 84 clinical cases (48 LSCC and 36 NC). In the validation cohort, the AUC of 5 individual miRNAs ranged from 0.721 to 0.837. The accuracy was further increased by the logistic model, which further increased the AUC to 0.959 by adjusting for the number of miRNAs. The mRNA-miRNA regulatory network and immune function analysis revealed the possible underlying pathogenesis of LSCC. Conclusions Exosomal miRNAs panel can be promising plasma biomarkers for predicting early diagnosis and prognosis in LSCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Sequencing and validation of exosomal miRNAs panel as novel plasma biomarkers for early diagnosis and prognosis prediction in laryngeal cancer

Zhang

Chen

Huang

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…They have also suggested that miR-153 is an independent prognostic biomarker to predict the 3-year survival of PDAC patients (Bai et al, 2015). A recent study by Baber et al (2021) shows that miR-153 expression was low in the peripheral blood of oral squamous cell carcinoma patients than normal individuals and speculated that expression of miR-153 in the serum can function as a diagnostic biomarker (Baber et al, 2021). The meta-analysis data also shows the correlation between low mir-153 expression and poor overall survival of cancer patient and suggest miR-153 as an effective biomarker for various type of cancer (Huang et al, 2020).…”

Section: Mir-153 As a Biomarker In Cancermentioning

confidence: 98%

miR-153 as biomarker for cancer—functional role as tumor suppressor

Thakur¹,

Saini²,

Das³

et al. 2022

Biocell

View full text Add to dashboard Cite

, belongs to a class of small non-coding RNA. It is a critical regulator of gene expression at the post-transcriptional level which interacts with the functional mRNA at 3'UTR region and suppresses the expression of the mRNA. More recently, it has become apparent that changes in the miR-153 expression lead to invasion, metastasis, angiogenesis and various types of tumor progression. This review summarizes the connection between dysregulation of miR-153 and various types of cancer progression. miR-153 regulates various signaling pathways to inhibit the proliferation and induce apoptosis in the cancer cell and also show synergistic activity with anticancer drugs. In addition to this, the oncogenic behavior of miR-153 and their use as a potential biomarker in cancer was also reviewed.

show abstract

“…Baber S et al (2021) focused on miRNA-153 and miRNA-455-5p, which have been described to play a critical role in oral cancer development. Interestingly, the authors observed that the expression levels of miRNA-153 were decreased in the blood samples of OSCC patients than in healthy individuals (−1.97-fold), while the expression levels of miRNA-455-5p were increased (2.5-fold), suggesting that the detection of these liquid biopsy-based miRNAs could represent an adjuvant diagnostic tool [145]. Similarly, Nakamura K and colleagues (2021) evaluated the expression levels of cancer-associated miRNAs in the serum samples from OSCC patients.…”

Section: Mirnasmentioning

confidence: 99%

Liquid Biopsy and Circulating Biomarkers for the Diagnosis of Precancerous and Cancerous Oral Lesions

Gattuso

Crimi

Lavoro

et al. 2022

ncRNA

View full text Add to dashboard Cite

Oral cancer is one of the most common malignancies worldwide, accounting for 2% of all cases annually and 1.8% of all cancer deaths. To date, tissue biopsy and histopathological analyses are the gold standard methods for the diagnosis of oral cancers. However, oral cancer is generally diagnosed at advanced stages with a consequent poor 5-year survival (~50%) due to limited screening programs and inefficient physical examination strategies. To address these limitations, liquid biopsy is recently emerging as a novel minimally invasive tool for the early identification of tumors as well as for the evaluation of tumor heterogeneity and prognosis of patients. Several studies have demonstrated that liquid biopsy in oral cancer could be useful for the detection of circulating biomarkers including circulating tumor DNA (ctDNA), microRNAs (miRNAs), proteins, and exosomes, thus improving diagnostic strategies and paving the way to personalized medicine. However, the application of liquid biopsy in oral cancer is still limited and further studies are needed to better clarify its clinical impact. The present manuscript aims to provide an updated overview of the potential use of liquid biopsy as an additional tool for the management of oral lesions by describing the available methodologies and the most promising biomarkers.

show abstract

Role of miR153 and miR455-5p Expression in Oral Squamous Cell Carcinoma Isolated from Plasma

Cited by 7 publications

References 25 publications

Sequencing and validation of exosomal miRNAs panel as novel plasma biomarkers for early diagnosis and prognosis prediction in laryngeal cancer

Sequencing and validation of exosomal miRNAs panel as novel plasma biomarkers for early diagnosis and prognosis prediction in laryngeal cancer

miR-153 as biomarker for cancer—functional role as tumor suppressor

Liquid Biopsy and Circulating Biomarkers for the Diagnosis of Precancerous and Cancerous Oral Lesions

Contact Info

Product

Resources

About